Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Elmer Hoekstra 1 , Asha M. Das 2 , Marcella Willemsen 1 , Marloes Swets 3 , Peter J.K. Kuppen 3 , Christien J. van der Woude 1 , Marco J. Bruno 1 , Jigisha P. Shah 4 , Timo L.M. ten Hagen 2 , John D. Chisholm 4 , William G. Kerr 5 , Maikel P. Peppelenbosch 1 , Gwenny M. Fuhler 1 1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 2 Department of Surgery, Section Surgical Oncology, Laboratory Experimental Surgical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 3 Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands 4 Department of Chemistry, Syracuse University, Syracuse, New York, United States of America 5 Department of Microbiology and Immunology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, United States of America Correspondence to: Gwenny M. Fuhler, email: g.fuhler@erasmusmc.nl Keywords: colorectal cancer, SHIP2, phosphatases, migration, small molecule inhibitor Received: April 29, 2016 Accepted: September 19, 2016 Published: September 28, 2016 ABSTRACT Colorectal cancer (CRC) is the second most common cause of cancer-related death, encouraging the search for novel therapeutic targets affecting tumor cell proliferation and migration. These cellular processes are under tight control of two opposing groups of enzymes; kinases and phosphatases. Aberrant activity of kinases is observed in many forms of cancer and as phosphatases counteract such “oncogenic” kinases, it is generally assumed that phosphatases function as tumor suppressors. However, emerging evidence suggests that the lipid phosphatase SH2-domain-containing 5 inositol phosphatase (SHIP2), encoded by the INPPL1 gene, may act as an oncogene. Just like the well-known tumor suppressor gene Phosphatase and Tensin Homolog (PTEN) it hydrolyses phosphatidylinositol (3,4,5) triphosphate (PI(3,4,5)P3). However, unlike PTEN, the reaction product is PI(3,4)P2, which is required for full activation of the downstream protein kinase B (PKB/Akt), suggesting that SHIP2, in contrast to PTEN, could have a tumor initiating role through PKB activation. In this work, we investigated the role of SHIP2 in colorectal cancer. We found that SHIP2 and INPPL1 expression is increased in colorectal cancer tissue in comparison to adjacent normal tissue, and this is correlated with decreased patient survival. Moreover, SHIP2 is more active in colorectal cancer tissue, suggesting that SHIP2 can induce oncogenesis in colonic epithelial cells. Furthermore, in vitro experiments performed on colorectal cancer cell lines shows an oncogenic role for SHIP2, by enhancing chemoresistance, cell migration, and cell invasion. Together, these data indicate that SHIP2 expression contributes to the malignant potential of colorectal cancer, providing a possible target in the fight against this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“In particular, inhibitors of the Epidermal Growth Factor Receptor (EGFR), which is often over-expressed in CRC, have shown promise in this disease [2–4].”
BackgroundGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“Regorafenib [8]) or selective kinase inhibitors (e.”
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Bunney, T. D., & Katan, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2842 · Cited by 400
Hong, Y., Downey, T., Eu, K. W., Koh, P. K., & Cheah, P. Y. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9305-4 · Cited by 319
Brooks, R., Fuhler, G. M., Iyer, S., Smith, M. J., Park, M.-Y., Paraiso, K. H. T., Engelman, R. W., & Kerr, W. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902844 · Cited by 140 · cited 3×
“Our results demonstrating reduced PKB phosphorylation in CRC cells upon inhibition of SHIP2 are in line with our earlier results demonstrating reduced PKB phosphorylation in hematopoietic cells upon inhibition of the SHIP1 isoform [12].”
BackgroundResultSelf-citationFuhler, G. M., Brooks, R., Toms, B., Iyer, S., Gengo, E. A., Park, M.-Y., Gumbleton, M., Viernes, D. R., Chisholm, J. D., & Kerr, W. G. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00178 · Cited by 109
Self-citation
Cited by
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131
Self-citationChan Wah Hak, L., Khan, S., Di Meglio, I., Law, A.-L., Lucken-Ardjomande Häsler, S., Quintaneiro, L. M., Ferreira, A. P. A., Krause, M., McMahon, H. T., & Boucrot, E. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0146-8 · Cited by 95
Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis
Pedicone, C., Fernandes, S., Dungan, O. M., Dormann, S. M., Viernes, D. R., Adhikari, A. A., Choi, L. B., De Jong, E. P., Chisholm, J. D., & Kerr, W. G. (2020) · Journal of Cell Science · doi:10.1242/jcs.238030 · Cited by 61
Self-citationGumbleton, M., Sudan, R., Fernandes, S., Engelman, R. W., Russo, C. M., Chisholm, J. D., & Kerr, W. G. (2017) · Science Signaling · doi:10.1126/scisignal.aam5353 · Cited by 43
Self-citationStructural basis for interdomain communication in SHIP2 providing high phosphatase activity
Le Coq, J., Camacho-Artacho, M., Velázquez, J. V., Santiveri, C. M., Gallego, L. H., Campos-Olivas, R., Dölker, N., & Lietha, D. (2017) · eLife · doi:10.7554/elife.26640 · Cited by 42
“Similar to SHIP1, SHIP2 functions as a tumor suppressor in glioblastoma, erythroleukemia and squamous cell carcinoma (Giuriato et al., 2002; Taylor et al., 2000; Yu et al., 2008), but is oncogenic in breast carcinomas and colorectal cancer (Hoekstra et al., 2016; Prasad et al., 2008).”
BackgroundTargeting SHIP1 and SHIP2 in Cancer
Pedicone, C., Meyer, S. T., Chisholm, J. D., & Kerr, W. G. (2021) · Cancers · doi:10.3390/cancers13040890 · Cited by 42
Self-citation
Metadata
- Authors
- Hoekstra, E., Das, A. M., Willemsen, M., Swets, M., Kuppen, P. J. K., van der Woude, C. J., Bruno, M. J., Shah, J. P., Hagen, T. L. M. T., Chisholm, J. D., Kerr, W. G., Peppelenbosch, M. P., & Fuhler, G. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-28
- Volume
- 7
- Issue
- 45
- Pages
- 73525-73540
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2529188937
- Cited by
- 57
- References
- 8
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.